Sacubitril/Valsartan Initiation Among Veterans Who Are Renin‐Angiotensin‐Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction

Sacubitril/Valsartan Initiation Among Veterans Who Are Renin‐Angiotensin‐Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction

Background Sacubitril/valsartan, a first‐in‐class angiotensin receptor neprilysin inhibitor, received US Food and Drug Administration approval in 2015 for heart failure with reduced ejection fraction (HFrEF). Our objective was to describe the sacubitril/valsartan initiation rate, associated characte...

Full description

Bibliographic Details
Main Authors: April F. Mohanty, Emily B. Levitan, Jordan B. King, John A. Dodson, Orly Vardeny, James Cook, Jennifer S. Herrick, Tao He, Olga V. Patterson, Patrick R. Alba, Patricia A. Russo, Engels N. Obi, Michelle E. Choi, James C. Fang, Adam P. Bress
Format: Article
Language:English
Published: Wiley 2021-10-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
angiotensin receptor neprilysin inhibitor
heart failure
medication
reduced ejection fraction
titration
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.120.020474

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.120.020474

Similar Items